F2G’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

F2G is a biotechnology company that develops and commercializes novel therapeutics for the treatment of rare fungal diseases. Read more

Ian Nicholson's photo - CEO of F2G

CEO

Ian Nicholson

CEO Approval Rating

88/100

Founded:

1998

Status:

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cidara is the top competitor of F2G. Cidara was founded in 2012, and its headquarters is in San Diego, California. Cidara is in the Biotechnology field. Cidara has 47 more employees than F2G.

Amplyx is seen as one of F2G's top competitors. Amplyx was founded in San Diego, California} in 2006. Amplyx operates in the Biotechnology industry. Compared to F2G, Amplyx generates $193M less revenue.

Scynexis is F2G's #3 rival. Scynexis's headquarters is in Jersey City, New Jersey, and was founded in 2000. Scynexis is in the Biotechnology industry. Scynexis generates 0.06% of F2G's revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $200M a good estimate for F2G's revenue?

Acquisitions

No recent acquisitions found related to F2G

F2G Funding History

$6.1M$12.1M$21.4M$51.4M$111.4M$138.8M$199.6M

Since F2G was founded in 1998, it has participated in 7 rounds of funding. In total F2G has raised $199.6M. F2G's last funding round was on Aug 2020 for a total of $60.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Aug 2020
$60.8M

Cowen Healthcare Investments

Debt
Nov 2018
$27.4M
Series E
Jun 2016
$60M
Equity
Sep 2012
$30M
Equity
Aug 2008
$9.2M
-

Total Funding: $199.6M

Since F2G was founded in 1998, it has participated in 7 rounds of funding. In total F2G has raised $199.6M. F2G's last funding round was on Aug 2020 for a total of $60.8M

Investments

No recent investments found related to F2G

F2G News

August 12, 2020FinSMEs

F2G Secures US $60.8M in Financing

F2G, a UK- and Austria-based biotech developing...... See more »
August 12, 2020Endpoints News

Novo backs 'breakthrough' antifungal player's $60M round - with a focus on rare mold infections

The plight of antibiotics developers has been well documented: chronically underfunded research, daun... See more »
August 12, 2020BioSpace

F2G Rakes in $60 Million to Support Olorofim Development

Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal ... See more »
June 10, 2020FinanzNachrichten

F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections

Olorofim is currently in Phase 2b development for the treatment of life-threatening fungal infections... See more »
June 10, 2020FirstWord Pharma

F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections

MANCHESTER, England and VIENNA, Austria, June 10, 2020 /PRNewswire/ -- F2G Ltd, a UK- and Austria-bas... See more »
March 11, 2020Medical Buyer

F2G Receives US FDA Orphan Drug Designation For Olorofim

F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fun... See more »
November 12, 2019Medical Buyer

F2G Receives US FDA Breakthrough Therapy

F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening syst... See more »

F2G Press Releases

Headquarters

Lankro Way Eccles

Manchester, EnglandM30 0LX

440-161-785-1270

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

F2G is a biotechnology company that develops and commercializes novel therapeutics for the treatment of rare fungal diseases. F2G was founded in 1998. F2G's headquarters is located in Manchester, England, GB M30 0LX. It has raised 199.6M in 7 rounds. ...

CEO

F2G's CEO, Ian Nicholson, currently has an approval rating of 88%. F2G's primary competitors are Cidara, Amplyx & Scynexis.

Website

f2g.com

Frequently Asked Questions about F2G

  1. When was F2G founded?

    F2G was founded in 1998
  2. Who is F2G's CEO?

    F2G's CEO is Ian Nicholson
  3. How much revenue does F2G generate?

    F2G generates $200M in revenue
  4. How much funding does F2G have?

    F2G has historically raised $199.6M in funding
  1. Where is F2G's headquarters?

    F2G's headquarters is in Manchester England, GB
  2. How many employees does F2G have?

    F2G has 21 employees
  3. What sector does F2G operate in?

    F2G is in Pharmaceuticals
  4. Who are F2G's competitors?

    F2G's top competitors are Cidara, Amplyx, Scynexis